BioCryst Pharmaceuticals, Inc.

Type	Public (NASDAQ: BCRX)
Founded	1986
Headquarters	Birmingham, Alabama, USA
Key people	Jon P. Stonehouse , President and Chief Executive Officer Stuart Grant, Chief Financial Officer
Industry	Healthcare
Products	Biotechnology
Revenue	$57.56 million USD (2008)
Employees	80 (2008)
Website	www.biocryst.com

BioCryst Pharmaceuticals, Inc. is a pharmaceutical company headquartered in Birmingham, Alabama.^[1] The company focuses on cancer, autoimmune diseases, and viral infections.^[1] The company's most notable function has been the production of the antiviral medication Peramivir, which was approved by the FDA for emergency use in the treatment of drug resistant influenza A virus subtype H1N1.^[2]

Contents 1 History 2 Pipeline 3 References 4 External links

[edit] History

The company was founded in 1986 by Charles E. Bugg, Ph.D. and John A. Montgomery, Ph.D. In March of 1994, BioCryst became a public company when it completed an Initial Public Offering by listing its shares on the NASDAQ stock exchange. In 2008 the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.^[3]

[edit] Pipeline

• Forodesine HCl, investigational purine nucleoside phosphorylase (PNP) inhibitor for the treatment of T- and B-cell mediated disorders.
• BCX-4208/R3421, a second generation purine nucleoside phosphorylase inhibitor with applications in autoimmune diseases.
• Peramivir is an experimental antiviral drug being developed for the treatment of influenza.

[edit] References

[edit] External links

• Official website